Serum tartrate-resistant acid phosphatase 5b or amino-terminal propeptide of type I procollagen for monitoring bisphosphonate therapy in postmenopausal osteoporosis?

Clinical Chemistry

Volumn 51, Issue 12, 2005, Pages 2382-2385

  Välimäki, Matti J ^a   Tähtelä, Riitta ^b  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b Mehilainen Oy   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ALENDRONIC ACID; BIOLOGICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; PLACEBO; PROCOLLAGEN; PROCOLLAGEN TYPE 1 AMINOPROPEPTIDE; RISEDRONIC ACID; TARTRATE RESISTANT ACID PHOSPHATASE 5B; UNCLASSIFIED DRUG; VITAMIN D;

ADULT; ARTICLE; BLOOD SAMPLING; BONE DENSITY; BONE TURNOVER; CALCIUM INTAKE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG EFFICACY; DRUG MONITORING; FEMALE; FRAGILITY FRACTURE; HUMAN; MAJOR CLINICAL STUDY; PATIENT COMPLIANCE; POSTMENOPAUSE OSTEOPOROSIS; RADIOIMMUNOASSAY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; VITAMIN BLOOD LEVEL; VITAMIN INTAKE;

ACID PHOSPHATASE; COLLAGEN TYPE I; DIPHOSPHONATES; DRUG MONITORING; FEMALE; HUMANS; ISOENZYMES; OSTEOPOROSIS, POSTMENOPAUSAL; TIME FACTORS;

EID: 28044461954     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2005.055749     Document Type: Article

References (16)

1. Rosen CJ, Chesnut CH III, Mallinak NJS. The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation. J Clin Endocrinol Metab 1997;82:1904-10.
2. Greenspan SL, Parker RA, Ferguson L, Rosen HN, Maitland-Ramsay L, Karpf DB. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women; a randomized clinical trial. J Bone Miner Res 1998;13:1431-8.
3. Ravn P, Hosking D, Thompson D, Cizza G, Wasnich RD, McClung M, et al. Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early postmenopausal intervention cohort study, J Clin Endocrinol Metab 1999;84:2363-8.
4. Clowes JA, Peel NF, Eastell R. The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab 2004;89:1117-23.
5. Blumsohn A, Eastell R. The performance and utility of biochemical markers of bone turnover: do we know enough to use them in clinical practice? Ann Clin Biochem 1997;34:449-59.
6. Hannon R, Blumsohn A, Naylor K, Eastell R. Response of biochemical markers of bone turnover to hormone replacement therapy: impact of biological variability. J Bone Miner Res 1998;13:1124-33.
7. Andersson G, Ek-Rylander B. The tartrate-resistant purple acid phosphatase of bone osteoclasts-a protein phosphatase with multivalent substrate specificity and regulation. Acta Orthop Scand 1995;66(Suppl 266):189-94.
8. Halleen JM, Kaija H, Stepan JJ, Vihko P, Väänänen HK. Studies on the protein tyrosine phosphatase activity of tartrate-resistant acid phosphatase. Arch Biochem Biophys 1998;352:97-102.
9. Halleen JM, Räisänen S, Salo JJ, Reddy SV, Roodman GD, Hentunen TA, et al. Intracellular fragmentation of bone resorption products by reactive oxygen species generated by osteoclastic tartrate-resistant acid phosphatase. J Biol Chem 1999;274:22907-10.
10. Halleen JM, Alatalo SA, Suominen H, Cheng S, Janckila AJ, Väänänen HK. Tartrate-resistant acid phosphatase 5b: a novel serum marker of bone resorption. J Bone Miner Res 2000;15:1337-45.
11. Hosking D, Adami S, Felsenberg D, Andia JC, Valimaki M, Benhamou L, et al. Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomised, placebo-controlled study. Curr Med Res Opin 2003;19:383-94.
12. Seibel MJ, Koeller M, van der Velden B, Diel I. Long-term variability of bone turnover markers in patients with non-metastatic breast cancer. Clin Lab 2002;48:579-82.
13. Tähtelä R, Seppänen J, Laitinen K, Katajamäki A, Risteli J, Välimäki MJ. Serum tartrate resistant acid phosphatase 5b in monitoring bisphosphonate treatment with clodronate: a comparison with urinary N-terminal telopeptide of type I collagen and serum type I procollagen aminoterminal propeptide. Osteoporos Int 2005;16:1109-16.
14. Eastell R, Barton I, Hannon RA, Chines A, Garnero P, Delmas PD. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 2003;18:1051-6.
15. Bauer DC, Black DM, Garnero P, Hochberg M, Ott S, Orloff J, et al; Fracture Intervention Trial Study Group. Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. J Bone Miner Res 2004;19:1250-8.
16. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005;90:1294-301.